Cargando…

Noninvasive imaging of tumor hypoxia after nanoparticle-mediated tumor vascular disruption

We have previously demonstrated that endothelial targeting of gold nanoparticles followed by external beam irradiation can cause specific tumor vascular disruption in mouse models of cancer. The induced vascular damage may lead to changes in tumor physiology, including tumor hypoxia, thereby comprom...

Descripción completa

Detalles Bibliográficos
Autores principales: Virani, Needa A., Kelada, Olivia J., Kunjachan, Sijumon, Detappe, Alexandre, Kwon, Jihun, Hayashi, Jennifer, Vazquez-Pagan, Ana, Biancur, Douglas E., Ireland, Thomas, Kumar, Rajiv, Sridhar, Srinivas, Makrigiorgos, G. Mike, Berbeco, Ross I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7380644/
https://www.ncbi.nlm.nih.gov/pubmed/32706818
http://dx.doi.org/10.1371/journal.pone.0236245
Descripción
Sumario:We have previously demonstrated that endothelial targeting of gold nanoparticles followed by external beam irradiation can cause specific tumor vascular disruption in mouse models of cancer. The induced vascular damage may lead to changes in tumor physiology, including tumor hypoxia, thereby compromising future therapeutic interventions. In this study, we investigate the dynamic changes in tumor hypoxia mediated by targeted gold nanoparticles and clinical radiation therapy (RT). By using noninvasive whole-body fluorescence imaging, tumor hypoxia was measured at baseline, on day 2 and day 13, post-tumor vascular disruption. A 2.5-fold increase (P<0.05) in tumor hypoxia was measured two days after combined therapy, resolving by day 13. In addition, the combination of vascular-targeted gold nanoparticles and radiation therapy resulted in a significant (P<0.05) suppression of tumor growth. This is the first study to demonstrate the tumor hypoxic physiological response and recovery after delivery of vascular-targeted gold nanoparticles followed by clinical radiation therapy in a human non-small cell lung cancer athymic Foxn1(nu) mouse model.